Vidyalakshmi Chandramohan

Overview:

The research work in my laboratory focuses on identifying novel immunotherapeutic targets for the treatment of brain tumors, specifically glioblastoma (GBM). My previous work includes the development of the dual-specific immunotoxin (IT) D2C7-IT, which is currently in Phase I clinical trials in recurrent GBM (rGBM) patients. My current research seeks to identify novel strategies to enhance the efficacy of D2C7-IT and other GBM-targeted cytotoxic therapies. In conjunction with this, my research includes the investigation of immune-related biomarkers to predict the clinical outcome of D2C7-IT therapy in patients with GBM.

Positions:

Associate Professor in Neurosurgery

Neurosurgery, Neuro-Oncology
School of Medicine

Associate Professor in Pathology

Pathology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 2006

Boston University

M.B.A. 2020

North Carolina State University

Postdoctoral Associate, Surgery

Duke University School of Medicine

Research Associate, Pathology

Duke University School of Medicine

Research Associate, Sr, Pathology

Duke University School of Medicine

Grants:

A Genetically Modified Poliovirus and Immunotoxin for Malignant Brain Tumors

Administered By
Neurosurgery, Neuro-Oncology Clinical Research
Awarded By
Brain Tumor Research Charity
Role
Investigator
Start Date
End Date

Determining the maximum tolerated dose of a recombinant immunotoxin targeting wildtype EGFR and Mutant EGFRvIII

Administered By
Neurosurgery, Neuro-Oncology Clinical Research
Awarded By
Uncle Kory Foundation
Role
Co Investigator
Start Date
End Date

Immunosequencing of poliovirus and immunotoxin treated brain tumor samples

Administered By
Pathology
Awarded By
Uncle Kory Foundation
Role
Co Investigator
Start Date
End Date

Immunotoxin and chemotherapy/PD-L1 combinations for glioblastoma

Administered By
Neurosurgery, Neuro-Oncology
Awarded By
Uncle Kory Foundation
Role
Principal Investigator
Start Date
End Date

PRECLINICAL THERAPEUTIC SCREENING FOR NEW THERAPIES FOR GLIOBLASTOMA MULTIFORME

Administered By
Neurosurgery, Neuro-Oncology Clinical Research
Awarded By
Jewish Communal Fund
Role
Investigator
Start Date
End Date

Publications:

Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.

Authors
Low, JT; Chandramohan, V; Bowie, ML; Brown, MC; Waitkus, MS; Briley, A; Stevenson, K; Fuller, R; Reitman, ZJ; Muscat, AM; Hariharan, S; Hostettler, J; Danehower, S; Baker, A; Khasraw, M; Wong, NC; Gregory, S; Nair, SK; Heimberger, A; Gromeier, M; Bigner, DD; Ashley, DM
MLA Citation
Low, Justin T., et al. “Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.Cancer Cell, vol. 40, no. 5, May 2022, pp. 439–40. Pubmed, doi:10.1016/j.ccell.2022.04.009.
URI
https://scholars.duke.edu/individual/pub1519621
PMID
35487217
Source
pubmed
Published In
Cancer Cell
Volume
40
Published Date
Start Page
439
End Page
440
DOI
10.1016/j.ccell.2022.04.009

Th17 Immunity in the Colon Is Controlled by Two Novel Subsets of Colon-Specific Mononuclear Phagocytes.

Intestinal immunity is coordinated by specialized mononuclear phagocyte populations, constituted by a diversity of cell subsets. Although the cell subsets constituting the mononuclear phagocyte network are thought to be similar in both small and large intestine, these organs have distinct anatomy, microbial composition, and immunological demands. Whether these distinctions demand organ-specific mononuclear phagocyte populations with dedicated organ-specific roles in immunity are unknown. Here we implement a new strategy to subset murine intestinal mononuclear phagocytes and identify two novel subsets which are colon-specific: a macrophage subset and a Th17-inducing dendritic cell (DC) subset. Colon-specific DCs and macrophages co-expressed CD24 and CD14, and surprisingly, both were dependent on the transcription factor IRF4. Novel IRF4-dependent CD14+CD24+ macrophages were markedly distinct from conventional macrophages and failed to express classical markers including CX3CR1, CD64 and CD88, and surprisingly expressed little IL-10, which was otherwise robustly expressed by all other intestinal macrophages. We further found that colon-specific CD14+CD24+ mononuclear phagocytes were essential for Th17 immunity in the colon, and provide definitive evidence that colon and small intestine have distinct antigen presenting cell requirements for Th17 immunity. Our findings reveal unappreciated organ-specific diversity of intestine-resident mononuclear phagocytes and organ-specific requirements for Th17 immunity.
Authors
Huang, H-I; Jewell, ML; Youssef, N; Huang, M-N; Hauser, ER; Fee, BE; Rudemiller, NP; Privratsky, JR; Zhang, JJ; Reyes, EY; Wang, D; Taylor, GA; Gunn, MD; Ko, DC; Cook, DN; Chandramohan, V; Crowley, SD; Hammer, GE
MLA Citation
Huang, Hsin-I., et al. “Th17 Immunity in the Colon Is Controlled by Two Novel Subsets of Colon-Specific Mononuclear Phagocytes.Front Immunol, vol. 12, 2021, p. 661290. Pubmed, doi:10.3389/fimmu.2021.661290.
URI
https://scholars.duke.edu/individual/pub1471158
PMID
33995384
Source
pubmed
Published In
Frontiers in Immunology
Volume
12
Published Date
Start Page
661290
DOI
10.3389/fimmu.2021.661290

ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY

Authors
Chandramohan, V; Evangelous, T; Lipp, ES; Hora, B; Bigner, DD; McLendon, RE; Ashley, DM
MLA Citation
Chandramohan, Vidyalakshmi, et al. “ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY.” Neuro Oncology, vol. 22, 2020, pp. 365–365.
URI
https://scholars.duke.edu/individual/pub1473564
Source
wos-lite
Published In
Neuro Oncology
Volume
22
Published Date
Start Page
365
End Page
365

STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA

Authors
Low, J; Bowie, M; Chandramohan, V; Fuller, R; Muscat, A; Brown, M; Hariharan, S; Hostettler, J; Briley, A; Danehower, S; Baker, A; Wong, N; Ashley, D
MLA Citation
Low, Justin, et al. “STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA.” Neuro Oncology, vol. 22, 2020, pp. 73–73.
URI
https://scholars.duke.edu/individual/pub1467742
Source
wos-lite
Published In
Neuro Oncology
Volume
22
Published Date
Start Page
73
End Page
73

CD226 Expression is Associated with Increased Survival in Pancreatic Cancer

Authors
Landa, K; Chandramohan, V; Gonen, M; Winter, JM; Lidsky, M; Shah, K; Zani, S; Blazer, DG; Gromeier, M; McLendon, R; Nair, S; Allen, P
MLA Citation
Landa, K., et al. “CD226 Expression is Associated with Increased Survival in Pancreatic Cancer.” Annals of Surgical Oncology, vol. 27, no. SUPPL 1, SPRINGER, 2020, pp. S128–S128.
URI
https://scholars.duke.edu/individual/pub1435705
Source
wos
Published In
Annals of Surgical Oncology
Volume
27
Published Date
Start Page
S128
End Page
S128